The pilot study conducted by Sunnybrook Health Sciences Centre aims to explore the dopaminergic mechanisms underlying apathy in Alzheimer's Disease (AD), a condition affecting up to 80% of AD patients. The findings could lead to the development of novel therapeutic strategies targeting apathy, which is currently inadequately addressed by existing cholinesterase inhibitors. Given the high prevalence of apathy in AD and the limited efficacy of current treatments, successful outcomes from this study may position the sponsor favorably in the neuropsychiatric drug market, potentially attracting interest from larger pharmaceutical companies for collaboration or acquisition. The study's implications extend beyond AD, as insights gained may inform treatment approaches for apathy in other neuropsychiatric disorders, broadening the market potential.